Publications by authors named "Romi Feddersen"
Article Synopsis
- Multiple myeloma (MM) is still an incurable cancer despite available therapies, with T-cell bispecific antibodies (TCBs) targeting BCMA and GPRC5D showing promise but facing issues like resistance and relapse due to antigen loss.
- Forimtamig is a novel GPRC5D-targeting TCB that works more effectively than traditional formats by forming stable immunological connections, leading to better tumor cell destruction and T cell activation in preclinical studies.
- Current research is exploring forimtamig in clinical trials for relapsed and refractory MM patients, both alone and alongside traditional care and new therapies, to enhance treatment outcomes and prevent relapses.
Article Synopsis
- The existing BRAF and MEK inhibitors used for treating BRAF V600E/K-mutated melanoma have limited and short-lived effectiveness, particularly in brain metastases, leading to a need for better treatments.
- Researchers introduced a new potent BRAF inhibitor (C1a) that works well as a first-line therapy and after patients have relapsed from standard treatments, showing superior results in lab and animal models.
- The study found that C1a remains effective despite some resistance mechanisms, identifying potential genetic causes of treatment failure and suggesting that combining C1a with anti-PD-1 therapy could further enhance treatment outcomes.
